# Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

> **NCT00372853** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 28 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** CP-675,206
- **DRUG:** SU011248
- **DRUG:** CP-675,206
- **DRUG:** SU011248

## Key facts

- **NCT ID:** NCT00372853
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372853, "Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00372853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*